Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Gratzke

Showing results (91-100 of 94) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 94 results.
BMC Cancer|March 30, 2022
Feasibility, pitfalls and results of a structured concept-development phase for a randomized controlled phase III trial on radiotherapy in primary prostate cancer patientsS K B Spohn, S Adebahr, M Huber, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 18, 2025
Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 studyC Gratzke, M Özgüroğlu, A Peer, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|March 8, 2013
Prediction of outcome in patients with urothelial carcinoma of the bladder following radical cystectomy using artificial neural networksA Buchner, M May, M Burger, et al.
Prostate Cancer and Prostatic Diseases|May 10, 2017
The survival impact of neoadjuvant hormonal therapy before radical prostatectomy for treatment of high-risk prostate cancerL Tosco, A Laenen, A Briganti, et al.
Pageof 10

Showing results (91-100 of 94) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 94 results.
BMC Cancer|March 30, 2022
Feasibility, pitfalls and results of a structured concept-development phase for a randomized controlled phase III trial on radiotherapy in primary prostate cancer patientsS K B Spohn, S Adebahr, M Huber, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 18, 2025
Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 studyC Gratzke, M Özgüroğlu, A Peer, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|March 8, 2013
Prediction of outcome in patients with urothelial carcinoma of the bladder following radical cystectomy using artificial neural networksA Buchner, M May, M Burger, et al.
Prostate Cancer and Prostatic Diseases|May 10, 2017
The survival impact of neoadjuvant hormonal therapy before radical prostatectomy for treatment of high-risk prostate cancerL Tosco, A Laenen, A Briganti, et al.
Pageof 10